How many ovarian cancer patients are eligible for fertility-sparing surgery?

Objective

To assess how many epithelial ovarian cancer (EOC) patients are eligible for fertility-sparing surgery (FSS) in a population-based study.

Study design

Using data from the Geneva Cancer Registry, we conducted a retrospective review of all women diagnosed with epithelial ovarian cancer (EOC) between January 1979 and December 2008. Patients were classified into two age groups (“young group” ≤ 45 years and “old group” > 45 years) and as “eligible for FSS” (FIGO IA, G1-G2 or unilateral ICG1) and “non-eligible for FSS” (FIGO IA, G3; IC G2-G3; IB or II–IV). Patients and tumor characteristics were tested with the chi-square test. Estimates of survival were calculated using the Kaplan-Meyer method and differences between groups were analyzed by the log-rank test.

Results

A total of 888 EOC patients were analyzed. The young group included 87 patients (9.8%): eleven (1.2%) were identified as eligible for FSS and 6 (0.6%) were nulliparous. The annual incidence of EOC women eligible for FSS in Geneva was 0.48/100,000 (0.5 women/year) and the expected annual incidence rate for Switzerland (8 million inhabitants) is 6.5 women/year.

Conclusion

Only a very small proportion of EOC patients are eligible for FSS. These results highlight the need to centralize FSS data in dedicated European units, in order to maintain expertise and quality of care for these patients.     

Does maternal obesity impact pregnancy-related deaths? Michigan experience

Obesity is a multifactorial non-communicable condition that has become a public health epidemic worldwide. The Fifth Millennium Development Goal established the goal of a 75% reduction in the maternal mortality ratio (MMR) between 1990 and 2015. Maternal mortality has been difficult to track over time. Obesity affects pregnancy in more than 50% of women of reproductive age in the state of Michigan; the potential impact of maternal obesity and pregnancy-related deaths (PRDs) has not been studied in Michigan. We conducted a secondary analysis of maternal death cases originally reviewed by the Michigan Maternal Mortality Review Committee from 2004 to 2006 seeking to evaluate the impact of maternal obesity on PRD. Two hundred and five maternal deaths occurred during the period of the study, 61 were classified as PRD. The observed occurrence of PRDs in the obese population was 36 cases while in the non-obese was 25 cases. The study showed a 3.7× risk of PRD in the obese parturient.     

Is dinoprostone safe? A report of three maternal deaths

We report three maternal deaths which might be in possible association with the use of intravaginal dinoprostone for cervical ripening and induction of labor. All cases occurred at our institution between January 2006 and December 2007. Uterine atony and profuse bleeding followed by disseminated intravascular coagulation (DIC), characterized by severe hypofibrinogenemia developed shortly after delivery of the first two patients. The third patient developed respiratory symptoms in the active labor followed by hemodynamic changes manifested by tetanic uterine contractions and fetal heart rate decelerations. Cardiac arrest developed in all patients shortly after the occurrence of symptoms with no response to any medical intervention. The pharmacologic induction of labor with dinoprostone may be in association with increased risk of maternal death because of increased risk of postpartum DIC and amnionic fluid embolism. Further investigations seem to be needed.     

How do maternal factors impact preeclampsia prediction in Brazilian population?

Objective: To evaluate the impacts of maternal risk factors described by the Fetal Medicine Foundation’s 2012 algorithm (FMF2012) in a Brazilian population.

Methods: All singleton pregnancies submitted to first-trimester preeclampsia (PE) screening using the FMF2012 algorithm were considered for study inclusion. Maternal factors, recorded via a patient questionnaire, were described and compared between PE outcome groups. A Gaussian regression model was derived to measure the effects of maternal factors, and to identify factors that contributed significantly (p?Results: Of the 1934 cases considered for study inclusion, the final sample consisted of 1531 cases. The sample included 120 (7.8%) cases of PE, of which 26 (1.7%) were preterm PE (PE?p?Conclusions: The significance and magnitude of associations of maternal factors in our sample differed from those incorporated in the FMF2012 model, implying the need to derive a fitted model for our population.     

How well are lesbians treated in UK fertility clinics?

Legislation regulating fertility treatment in the United Kingdom originally discouraged treatment without a father, resulting in many clinics denying access to lesbian couples. Lesbians now enjoy rights to legal union, dual parenthood and protection against discrimination. Consequently, increasing numbers seek fertility treatment. This is a growing stakeholder group, but it is unknown whether UK licensed centres are serving them adequately. Data from the Human Fertilisation and Embryology Authority suggests live birth rates after in vitro fertilisation for lesbians is comparable to estimates for natural attempt at pregnancy for heterosexuals, whereas success rates with donor insemination are lower. Unsurprisingly, live birth rates for lesbians after in vitro fertilisation are higher compared with heterosexual couples (the latter attending with fertility issues). However, outcomes for lesbians after donor insemination are slightly lower, potentially due to increased female age. Rather than adopting a one-heterosexual-size-fits-all approach, lesbian couples may benefit from new treatment pathways. They also have a different experience of fertility treatment, some reporting a wish to be presumed fertile rather than medicalised, and others encountering heterosexism by fertility professionals. Additionally, some lesbians with known fertility issues have needed to resort to legal action to obtain the publicly funded treatment they are entitled to.     

Unexplained antepartum fetal deaths: what are the determinants?

Objective The objective was to assess fetal, antenatal, and pregnancy determinants of unexplained antepartum fetal death.Methods This is a hospital-based cohort study of 34,394 births weighing 500 g or more from January 1995 to December 2002. Unexplained fetal deaths were defined as fetal deaths occurring before labor, without evidence of significant fetal, maternal or placental pathology.Results Ninety-eight unexplained antepartum fetal deaths accounted for 27.2% of 360 total fetal deaths. Two-thirds of these deaths occurred after 36 weeks gestation. The following factors are independently associated with unexplained fetal deaths: primiparity (OR 1.74; 95% CI 1.21, 2.86); parity of five or more (OR 1.19; 95% CI 1.26, 3.26); low socioeconomic status (OR 1.22; 95% CI 1.14, 2.86); maternal age 40 years or more (OR 3.62; 95% CI 1.22, 4.52); maternal age of 18 years or less (OR 1.79; 95% CI 0.82, 2.89); maternal prepregnancy weight greater than 70 kg (OR 2.20; 95% CI 1.85, 3.68); fewer than three antenatal visits in women whose fetuses died at 31 weeks or more (OR 1.11; 95% CI 1.08, 2.48); birth weight ratio (defined as ratio of birth weight to mean birth weight for gestational age) between 0.85 and 0.94 (OR 1.77; 95% CI 1.28, 4.18) or over 1.45 (OR 2.92; 95% CI 1.75, 3.21); trimester of first antenatal visit. Previous fetal death, previous abortion, cigarette smoking, fetal sex, low maternal weight, fetal-to-placenta weight, and post date pregnancy were not significantly associated with unexplained fetal deaths.Conclusion Several factors were identified that are associated with an increased risk of unexplained fetal deaths.     

Breast cancer in men: are there similarities with breast cancer in women?

Male breast cancer is an uncommon disease although its incidence has increased over the recent years. Like other orphan diseases, male breast cancer is understudied. This disease has a lot of similarities with female breast cancer. Some differences are yet noticeable. This article describes three cases of carcinoma of the breast in men with a review of the literature on risk factors and treatment. A database must be started with epidemiologic information to understand this disease and its correlation with breast cancer in women.